SPOTLIGHT: Wyeth R&D chief exits with kudos for success

The blogsters at In Vivo have weighed in on the news that Wyeth R&D chief Bob Ruffolo is retiring. He may have been tough to get along with, but the blog gives Ruffolo credit for some significant achievements in new drug approvals at a time most of the industry has been experiencing a long, dry spell. Ruffolo had early on noted the rising number of mid-stage trials that were failing, noting that the only sensible response was to increase the number of experimental therapies in the pipeline. All eyes now turn to the new R&F chief, Mikael Dolsten. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."